Skip to search formSkip to main contentSkip to account menu

Exceptional Responder

A cancer patient showing either a complete disease response, or a partial disease response of at least 6 months duration in a trial or treatment… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Anti-tumor immune responses in metastatic breast cancer exceptional responder patients.
e15161Background: Analyzing anti-cancer immune responses can offer insights into the mechanisms that underlie successful cancer… 
2018
2018
First-inhuman trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients
RESULTS. Among the 27 patients enrolled the median age was 54 years. None of 19 patients treated at dose level 1 (cetuximab i.v… 
Review
2017
Review
2017
Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature
We present the case of a 53-year-old male with metastatic rectal cancer who was treatment resistant to FOLFOX and FOLFOXIRI. Due… 
2017
2017
Abstract 1177: Targeting NEDD8 to uncover an exceptional responder molecular subtype in glioblastoma
2016
2016
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic…
We used next-generation sequencing to identify somatic alterations in multiple metastatic sites from an “exceptional responder… 
2016
2016
EXTH-54. TARGETING NEDD8 TO UNCOVER AN EXCEPTIONAL RESPONDER MOLECULAR SUBTYPE IN GLIOBLASTOMA
actions Neddylation is a post-translational mechanism that marks proteins for degradation through activity of NEDD8 Activating… 
2015
2015
Abstract 3898: Exome analysis of an exceptional responder uncovers an activating GNAS mutation that may confer sensitivity to cytotoxic chemotherapy
2014
2014
RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?
SUMMARY In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely… 
2014
2014
Learning from exceptional drug responders
The US National Cancer Institute is launching an 'exceptional responder' programme to see whether outliers from failed cancer… 
2014
2014
Cancer centers zero in on exceptional responders
703 Cancer patients who make remarkable recoveries will be studied systematically in two largescale translational oncology… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)